CHERYL BAYENS: Open Payments
NPI 1679967673 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,993 in 139 payments from 19 companies in 2025. Trend: 2023 $3,029 · 2024 $3,126 · 2025 $2,993
Food & beverage: $2,993
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 43 | $945 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $503 |
| GENZYME CORPORATION | 8 | $357 |
| Madrigal Pharmaceuticals | 13 | $246 |
| Aimmune Therapeutics, Inc. | 9 | $157 |
| Regeneron Healthcare Solutions, Inc. | 6 | $145 |
| QOL Medical, LLC | 5 | $106 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $87 |
| Ipsen Biopharmaceuticals, Inc | 3 | $63 |
| Ardelyx, Inc. | 4 | $60 |
Products named: DUPIXENT, RINVOQ, ENTYVIO, REZDIFFRA, MAVYRET, ZENPEP, CREON, Sucraid.
Industry payments across MO — which companies pay providers there.
